Treatment

Providers Clinical Support System: SUD 101 Core Curriculum

Clinical experts from the Providers Clinical Support System (PCSS) created the Substance Use Disorder 101 Core Curriculum for Healthcare Professionals. With the addition of two new module topics, the 23 modules in this 2023 curriculum provide an overview of evidence-based practices in the prevention, identification, and treatment of substance use disorders and co-occurring medical and psychiatric conditions for a variety of populations.
Posted Date
03/15/24

Substance Use Disorders and Treatment Among Jail Populations: Curated Resource List for Corrections Staff

The Bureau of Justice Assistance (BJA), Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP), and Advocates for Human Potential, Inc. (AHP) has provided a curated resource list for corrections officers and other jail staff members manage the well-being of individuals in jail custody who have SUD. The categories of resources were prioritized by participants in a jail practitioner roundtable on opioid-related training needs convened by the Bureau of Justice Assistance.
Posted Date
11/17/23

University of Rochester: Free Training on Treatment of Opioid Use Disorder in Primary Care

The University of Rochester Recovery Center of Excellence, one of three FORHP-supported Rural Centers of Excellence on Substance Use Disorder, has developed comprehensive training on the treatment of opioid use disorder (OUD) in primary care. This no-cost training prepares providers and staff to deliver evidence-based care to patients. Continuing education credits are available.
Posted Date
10/15/23

National Report: Rural Substance Use Disorder Stigma and Treatment Needs

The University of Vermont Center on Rural Addiction (UVM CORA), the University of Rochester, and the Fletcher Group have conducted an online survey assessing SUD stigma (including stigmatizing language), treatment needs and barriers, and concerns through the perspectives of rural, RCORP-affiliated practitioners. The data report explores the findings of the survey, including practitioner recommendations on improving access to OUD treatment.
Posted Date
09/28/23

RSV 2023 Session: Evidence-Based Treatment of OUD in the Era of Fentanyl (Day 1)

This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted Date
07/26/23

The Kaiser Family Foundation (KFF) Examines Federal Policy for Substance Use Disorder Treatment

A new analysis from health policy researchers at the Kaiser Family Foundation (KFF) gives an overview of five federal policies for substance use disorder (SUD) and the ways they changed during the pandemic.  The report covers regulations related to buprenorphine medication, methadone dispensing programs, Medicaid for SUD treatment in prisons, and how state laws may limit federal efforts.  An action taken by the federal Drug Enforcement Administration in 2021 was cited as potentially beneficial to rural areas because it would allow mobile units for accredited op

Posted Date
07/21/23

Providers Clinical Support System Releases Fentanyl Treatment Guidelines

Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Posted Date
05/26/23

Contingency Management for Stimulant Use Disorder: Progress, Challenges, and Recommendations

Contingency management has empirical support but limited implementation. This report provides an overview of contingency management, barriers of implementation, and recommendation on how to overcome the challenges of implementation. Evidence-based treatment for people with stimulant use disorder is important as the U.S. has been experiencing an overdose crisis resulting in overdose deaths. 
Posted Date
03/14/23

Removal of DATA Waiver (X-Waiver) Requirement

The Consolidated Appropriations Act of 2023 removed the federal requirement for providers to have an X-waiver to prescribe medications for the treatment of OUD. The act amended the Controlled Substances Act. Depending on state law, practitioners who have a current DEA registration with Schedule III authority will be able to prescribe buprenorphine for OUD starting now.
Posted Date
01/17/23